KYORIN PHARMACEUTICAL CO., LTD.
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1958-10-31
- Employees
- 2K
- Market Cap
- $650.6M
Clinical Trials
88
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (85 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Kyorin Pharmaceutical Co.,Ltd
- Target Recruit Count
- 99
- Registration Number
- NCT04908800
- Locations
- 🇬🇧
Labcorp Clinical Research, Leeds, United Kingdom
Survey on the Effect of Health Related Quality of Life (QOL) Associated With Compliance of Carbocisteine in Asthma Patients
- Conditions
- Asthma
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2013-03-01
- Lead Sponsor
- Kyorin Pharmaceutical Co.,Ltd
- Target Recruit Count
- 179
- Registration Number
- NCT01693471
- Locations
- 🇯🇵
Senzoku Respiratory Disease and Allergy Clinic, Ota-ku, Tokyo, Japan
Observational Study in the Management of Ulcerative Colitis With Oral 5-ASA
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Kyorin Pharmaceutical Co.,Ltd
- Target Recruit Count
- 5704
- Registration Number
- NCT01654783
- Locations
- 🇯🇵
Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
OASIS STUDY Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS STUDY)
- Conditions
- Stroke
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kyorin Pharmaceutical Co.,Ltd
- Target Recruit Count
- 2069
- Registration Number
- NCT00281034
- Locations
- 🇯🇵
Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital, Tachikawa-City, Tokyo, Japan
News
Eisai Launches Beova Tablets for Overactive Bladder Treatment in Thailand
Eisai Thailand has launched Beova® Tablets (vibegron), a selective β3-adrenergic receptor agonist for overactive bladder treatment, marking the first market entry in Eisai's licensed ASEAN region.
New Global Review Reveals Comprehensive Landscape of Interstitial Cystitis Clinical Trials in 2025
• A newly released global clinical trials review provides extensive data on Interstitial Cystitis research, tracking trial numbers and enrollment trends across major countries worldwide. • The report categorizes trials by region, phase, status, and sponsorship, highlighting key pharmaceutical companies including Astellas Pharma, AbbVie, Johnson & Johnson, and Pfizer as prominent sponsors. • This comprehensive analysis serves as a strategic resource for stakeholders making investment decisions in IC research, offering insights into trial success rates and identifying optimal locations for clinical studies.